Cortexyme, which is developing a novel therapy for Alzheimer's disease using a microbe inhibitor, raised $75 million by offering 4.4 million shares at $17, the midpoint of the $16 to $18 range. Cortexyme plans to list on the Nasdaq under the symbol CRTX. BofA Merrill Lynch and Credit Suisse acted as lead managers on the deal.
